Multidisciplinary Seminars and Insights ( III year)
A.Y. 2024/2025
Learning objectives
The course is focused on a deepening of biotechnological drugs, with particular attention to recombinant proteins for the cardiovascular sistem and to anticancer tumors. Students will learn :
- to understand what biotenologies and recombinant DNA technologies are;
- what are recombinant therapeutic proteins and how to obtaine them;
- to have an overview of the therapeutic proteins used as antifibrinolytics and hematopoietic;
- to understand what are monoclonal and their use in oncology;
- to understand which are the "new drugs and pharmacological targets": brief mention of epigenent mechanisms and epidrugs, mediated cell therapies and genome editing
- to understand what biotenologies and recombinant DNA technologies are;
- what are recombinant therapeutic proteins and how to obtaine them;
- to have an overview of the therapeutic proteins used as antifibrinolytics and hematopoietic;
- to understand what are monoclonal and their use in oncology;
- to understand which are the "new drugs and pharmacological targets": brief mention of epigenent mechanisms and epidrugs, mediated cell therapies and genome editing
Expected learning outcomes
The learning outcomes will focus on
- verify if the student has learned and re-elaborated the basic concepts inherent to therapeutic proteins: what and which are, how they are obtained and how they can be modified;
- check if the student is aware of the existence of new pharmacological targets and innovative therapies.
- verify if the student has learned and re-elaborated the basic concepts inherent to therapeutic proteins: what and which are, how they are obtained and how they can be modified;
- check if the student is aware of the existence of new pharmacological targets and innovative therapies.
Lesson period: Second semester
Single course
This course can be attended as a single course.
Course syllabus and organization
Single session
Course syllabus
1) Biotechnology and recombinant DNA technologies;
2) recombinant Therapeutic proteins and how they are obtained;
3) Overview of therapeutic proteins used as antifibrinolytics and hematopoietics;
4) Monoclonal antibodies and lotus use in oncology;
5) "new drugs and pharmacological targets": brief mention of epigenetic mechanisms and epidrugs, cell-mediated and genome editing therapies
2) recombinant Therapeutic proteins and how they are obtained;
3) Overview of therapeutic proteins used as antifibrinolytics and hematopoietics;
4) Monoclonal antibodies and lotus use in oncology;
5) "new drugs and pharmacological targets": brief mention of epigenetic mechanisms and epidrugs, cell-mediated and genome editing therapies
Prerequisites for admission
No prior knowledge is required
Teaching methods
The courses will include lectures with the possible addition of laboratory exercises
Teaching Resources
BIOTECNOLOGICI - VEGETO MAGGI MINGHETTI, Ed. CEA
Assessment methods and Criteria
The exam will be written. It will mainly consist of multiple choice questions with the addition of some open questions, in addition it will be possible, at the discretion of the teacher, to carry out an additional oral test.
Professor(s)